Report Highlights

How the visceral leishmaniasis market works: Supply Chain Explained

The supply chain for visceral leishmaniasis therapeutics begins with active pharmaceutical ingredient (API) synthesis for the four primary treatment compounds: liposomal amphotericin B, miltefosine, sodium stibogluconate, and meglumine antimoniate. Amphotericin B fermentation relies on Streptomyces nodosus cultures, with bulk fermentation concentrated in India and the United States. Miltefosine API is produced predominantly by Zentaris-derived chemical synthesis routes, with secondary API sourcing from Indian contract manufacturers in Hyderabad and Mumbai. Pentavalent antimonials — sodium stibogluconate and meglumine antimoniate — are manufactured by Albert David in India and Sanofi in France respectively, using antimony trioxide as the primary mineral input, which is sourced overwhelmingly from China's Hunan and Guangxi provinces. Each API undergoes formulation — liposomal encapsulation for amphotericin B is a technically demanding lipid bilayer process performed at specialist fill-finish facilities in the United States and Europe before WHO prequalification testing and cold-chain packaging.

Finished products reach end customers through three distinct procurement channels: multilateral procurement via the Drugs for Neglected Diseases initiative (DNDi) and UNICEF Supply Division, bilateral government procurement under national elimination programmes in India, Bangladesh, and Nepal, and commercial pharmacy channels in Brazil and Mediterranean Europe. Lead times from manufacturer to endemic-country health facility typically run 90 to 180 days due to regulatory import clearance and cold-chain logistics requirements for amphotericin B formulations. Pricing mechanisms are tiered: Gilead supplies AmBisome to public health programmes at a negotiated concessional rate of approximately USD 15 per vial versus a commercial price exceeding USD 200, compressing margin entirely into the donation framework. Diagnostic supply — primarily rK39 rapid tests manufactured by InBios International and SD Biosensor in South Korea — follows a shorter lead-time pathway of 30 to 60 days through WHO Emergency Use Listing channels.

Visceral leishmaniasis market dynamics

The visceral leishmaniasis market operates under a dual-track pricing structure that separates public health procurement from commercial sales, creating an unusual power dynamic where multilateral buyers — principally WHO, UNICEF, and national elimination programme offices — set effective price ceilings for the majority of global volume. The Indian subcontinent accounts for over 70% of global case burden, meaning that Indian government procurement terms functionally establish global reference pricing for first-line therapies. This concentration of buyer power suppresses commercial margins and has historically deterred private pharmaceutical investment in new chemical entities. Contract structures lean heavily toward long-term framework agreements with donor-funded price guarantees, rather than spot market transactions, limiting pricing volatility but also reducing incentive for supply-side innovation.

Market differentiation increasingly occurs at the diagnostic layer rather than the therapeutic layer. The rK39 antigen-based rapid diagnostic test has become effectively commoditised, with multiple WHO-prequalified manufacturers competing primarily on price and lead time. Differentiation among therapeutic suppliers centres on regulatory status — WHO prequalification and stringent regulatory authority approval carry significant procurement advantages — cold-chain capability, and ability to meet volume commitments under framework contracts. Information asymmetry is most acute in Africa, where case surveillance is incomplete, causing endemic countries to underestimate true disease burden and consequently under-procure diagnostics and treatments, creating cyclical under-supply in East African markets including Ethiopia, Sudan, and South Sudan.

Growth drivers fuelling visceral leishmaniasis expansion

Climate-driven expansion of the Phlebotomus sandfly vector habitat is the most structurally significant demand driver. Rising temperatures and shifting rainfall patterns are extending viable sandfly territory northward into southern Europe and Central Asia, and at higher altitudes across the East African highlands, directly increasing the at-risk population. This geographic expansion translates into supply chain demand at the diagnostic input stage first — rK39 test kit procurement rises before therapeutic volumes, as new endemic zones require surveillance infrastructure before treatment programmes are established. Manufacturers of nitrocellulose membranes and colloidal gold conjugates used in lateral flow diagnostics, primarily supplied from manufacturing hubs in China and India, face incremental but sustained volume increases tied directly to this epidemiological shift.

The second major driver is the WHO 2030 roadmap target for visceral leishmaniasis elimination as a public health problem in the Indian subcontinent, which is accelerating procurement volume and supply chain formalisation within the India-Bangladesh-Nepal transmission corridor. This political commitment unlocks additional donor financing from Gavi and the Global Fund, increasing purchase volumes and extending planning horizons for manufacturers. The third driver is co-infection complexity: HIV-visceral leishmaniasis co-infection, particularly prevalent in Ethiopia and Brazil, requires combination therapy protocols that increase per-patient drug consumption and demand for second-line agents including amphotericin B lipid complex formulations, pulling volume through higher-cost supply chain nodes and increasing average revenue per treatment episode by a factor of two to three versus standard monotherapy.

Supply chain risks and market restraints

The most acute supply chain risk is geographic concentration of antimony trioxide sourcing. China supplies over 80% of global antimony trioxide, the mineralogical precursor to pentavalent antimonial drugs still used as first-line treatment in parts of Africa and Latin America. Any Chinese export restriction, environmental regulatory tightening at smelters in Hunan Province, or trade disruption directly threatens the supply of sodium stibogluconate and meglumine antimoniate at a stage in the supply chain — primary mineral input — that cannot be rapidly substituted. Albert David in Kolkata and Sanofi in France hold limited buffer inventories, typically under 90 days of cover, amplifying exposure to upstream disruption. This risk sits at the raw material extraction node and falls most heavily on public procurement agencies in East Africa that still rely on antimonials as primary therapy.

A secondary constraint is the cold-chain logistics dependency of liposomal amphotericin B. AmBisome requires refrigerated storage at 2–8°C throughout the distribution chain, placing significant infrastructure demands on endemic-country logistics systems in South Sudan, Bihar state in India, and rural Ethiopia, where cold-chain failure rates at the last mile exceed 15% in documented health facility audits. This cold-chain dependency acts as a hard ceiling on accessibility in the highest-burden geographies, effectively restraining treatment uptake regardless of procurement volume or pricing. Regulatory restraints compound the problem: miltefosine's teratogenicity classification requires pregnancy testing before dispensing, adding a gatekeeping step that delays treatment initiation by three to seven days in low-resource settings where laboratory access is limited.

Where visceral leishmaniasis growth opportunities are emerging

The strongest near-term opportunity lies in thermostable oral formulation development for miltefosine. Eliminating cold-chain dependency while retaining oral bioavailability would simultaneously remove the largest access barrier in sub-Saharan Africa and reduce last-mile logistics costs by an estimated 40 to 60%. The value capture from this innovation sits at the formulation and IP layer rather than the API stage, favouring speciality pharmaceutical companies with drug delivery technology platforms. DNDi has already initiated preclinical work on novel miltefosine analogues with improved thermostability, and early-stage partnerships with Indian generic manufacturers position the Indian subcontinent as both the manufacturing base and the primary beneficiary market for any successful development outcome.

A second structural opportunity is the expansion of private-sector diagnostic distribution in Brazil and the Mediterranean basin, where visceral leishmaniasis caused by L. infantum in domestic dogs creates a parallel veterinary diagnostic and prophylactic market that is substantially larger by revenue than the human health channel. Canine leishmaniasis vaccines — led by Virbac's Letifend — and diagnostic kits generate commercial-rate margins unavailable in the human public health segment. Supply chain participants serving both veterinary and human channels achieve economies of scale in antigen production, cold-chain logistics, and regulatory compliance that single-channel operators cannot replicate. A third opportunity is point-of-care molecular diagnostics: portable PCR platforms adapted from COVID-19 testing infrastructure are being trialled in Bihar and Ethiopia, with the potential to replace rK39 tests in co-infection cases where antigen sensitivity is reduced, opening a higher-margin diagnostic segment.

Market at a Glance

Regional supply and demand map

On the supply side, India dominates API and finished-dose manufacturing for the global visceral leishmaniasis market. Sun Pharmaceutical, Cipla, and Strides Pharma Science produce miltefosine and generic amphotericin B formulations in Gujarat and Maharashtra, exporting to WHO procurement channels and directly to national health programmes. France remains the sole manufacturing source for meglumine antimoniate (Glucantime) through Sanofi's Amilly facility. The United States, through Gilead's contract manufacturing network, supplies the majority of WHO-prequalified liposomal amphotericin B. South Korea's SD Biosensor and InBios International in the US supply the rK39 rapid diagnostic test kits that anchor surveillance programmes globally, with antigen components sourced from recombinant expression systems in the Republic of Korea.

Demand is concentrated in three distinct geographic clusters. The Indian subcontinent — Bihar state in India, the Terai plains of Nepal, and northern Bangladesh — accounts for the largest single demand node, driven by the WHO elimination programme. East Africa, particularly Ethiopia, Sudan, South Sudan, and Kenya, represents the fastest-growing demand region, with case volumes rising due to climate-driven range expansion and persistent conflict-related healthcare disruption. Brazil is the dominant demand centre in Latin America, with both human and canine visceral leishmaniasis creating a structurally distinct commercial-plus-public procurement market. Trade flow imbalances are most pronounced in East Africa, where domestic manufacturing capacity is absent and all therapeutics are imported, making the region fully dependent on international supply chains and creating pricing vulnerability when global freight costs or Indian export regulations tighten.

Leading Market Participants

• Gilead Sciences
• Sanofi
• Sun Pharmaceutical Industries
• Cipla
• Strides Pharma Science
• Bharat Serums and Vaccines
• Albert David
• InBios International
• SD Biosensor
• Virbac

Long-term visceral leishmaniasis outlook

By 2034, the supply chain structure for visceral leishmaniasis therapeutics will shift materially as Gilead's donation agreement for AmBisome approaches renegotiation and Indian generic manufacturers — principally Bharat Serums and Sun Pharma — scale liposomal amphotericin B production to WHO prequalification standard. This transition will reduce average procurement cost per treatment course by 25 to 35% and redistribute manufacturing value concentration from the United States to the Indian subcontinent. Simultaneously, the projected WHO certification of visceral leishmaniasis elimination in the Indian subcontinent will redirect primary demand growth toward East Africa and Brazil, requiring supply chains to re-orientate distribution infrastructure away from South Asian delivery corridors toward Addis Ababa and Nairobi-based regional health commodity hubs.

The most valuable supply chain positions in 2034 will be thermostable oral formulation ownership, WHO-prequalified liposomal amphotericin B manufacturing, and high-sensitivity point-of-care molecular diagnostics. DNDi and its pharmaceutical development partners — including Drugs for Neglected Diseases initiative's ongoing engagement with Eisai and AstraZeneca on combination regimens — are best positioned at the innovation node. Among commercial participants, Sun Pharmaceutical Industries and Strides Pharma Science hold the strongest position to capture mid-chain manufacturing value as generic competition intensifies and procurement volumes shift geographically. Virbac retains a defensible position in the veterinary leishmaniasis segment in Europe and Brazil, where commercial pricing dynamics are insulated from the donor-driven pricing compression that constrains human health market margins.

Market Segmentation

By Product Type

• Liposomal Amphotericin B
• Miltefosine
• Sodium Stibogluconate
• Meglumine Antimoniate
• Rapid Diagnostic Tests (rK39)
• Molecular Diagnostics

By End User

• Public Health Programmes
• Hospital Pharmacies
• NGO and Humanitarian Procurement
• Veterinary Clinics
• Research Institutions

By Distribution Channel

• Multilateral Procurement (UNICEF, WHO)
• Government Direct Procurement
• Commercial Pharmacy
• Humanitarian Supply Chains

By Geography

• South Asia
• East Africa
• Latin America
• Mediterranean Europe
• Middle East

Frequently Asked Questions

Q1. What is the primary raw material constraint in the visceral leishmaniasis supply chain? ▼

Antimony trioxide, sourced over 80% from China, is the critical mineral input for pentavalent antimonial drugs. Any Chinese export restriction directly threatens sodium stibogluconate and meglumine antimoniate supply with fewer than 90 days of buffer inventory held by manufacturers.

Q2. Why does cold-chain dependency restrict treatment access in high-burden regions? ▼

Liposomal amphotericin B requires refrigeration at 2–8°C throughout distribution, and cold-chain failure rates at health facility level exceed 15% in rural Bihar and South Sudan. This infrastructure gap constrains treatment uptake independent of procurement volume or drug pricing.

Q3. How does WHO prequalification affect market access for manufacturers? ▼

WHO prequalification is a prerequisite for supply to UNICEF and most bilateral government procurement frameworks, effectively functioning as a market entry barrier. Manufacturers without it are excluded from the channels that represent over 70% of global visceral leishmaniasis treatment volume.

Q4. Which trade flow carries the highest concentration risk for diagnostic supply? ▼

South Korea-to-endemic-country flows for rK39 rapid diagnostic test kits carry the highest concentration risk, as SD Biosensor and InBios supply the majority of WHO-prequalified lateral flow diagnostics. Any Korean manufacturing disruption propagates immediately to surveillance programmes in East Africa and South Asia.

Q5. How does the canine leishmaniasis market in Europe affect the human health supply chain? ▼

Canine leishmaniasis in Mediterranean Europe and Brazil creates shared antigen production and cold-chain logistics infrastructure with the human diagnostic segment. Virbac and other veterinary players achieve scale economies in recombinant antigen manufacturing that lower per-unit input costs for the broader leishmaniasis diagnostics supply base.